Vitrolife ABOSTO:VITR -0.92%79 OCF Yield % is 5.98 as of Jul. 05, 2026, which is 186% above its 10-year median of 2.09. GuruFocus rates OSTO:VITR with a GF Score™ of 79/100 and a GF Value™ of kr162.23 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Vitrolife AB ranks better than 71.51% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Vitrolife AB's OCF Yield % or its related term are showing as below:
OSTO:VITR'
s OCF Yield % Range Over the Past 10 Years
Min: 0.55 Med: 2.09 Max: 6.08
Current: 5.98
During the past 13 years, the highest OCF Yield % of Vitrolife AB was 6.08%. The lowest was 0.55%. And the median was 2.09%.
OSTO:VITR's OCF Yield % is ranked better than 71.51% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs OSTO:VITR: 5.98
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vitrolife AB OCF Yield % Related Terms
Vitrolife AB OCF Yield % Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:VITR vs ABT, SYK, MDT: OCF Yield % Comparison
For the Medical Devices subindustry, Vitrolife AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (OSTO:VITR) has a OCF Yield % of 5.98 as of Jul. 05, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Vitrolife AB and its competitors. This is 186% above median its historical median of 2.09. Over the past decade, Vitrolife AB's OCF Yield % has ranged from 0.55 to 6.08. According to the industry distribution chart, Vitrolife AB ranks #243 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 28.5%.
Is Vitrolife AB's OCF Yield % too high?
Vitrolife AB's current OCF Yield % of 5.98 is 186% above median its 10-year median of 2.09. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 6.08. The Medical Devices & Instruments industry median OCF Yield % is 1.68. Vitrolife AB's value of 5.98 is 256% above this industry median. Based on the distribution chart, Vitrolife AB ranks #243 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #243 out of 853 companies for OCF Yield %. This puts Vitrolife AB in the upper half of its industry. The industry median OCF Yield % is 1.68. Vitrolife AB's value of 5.98 is 256% above this benchmark. Historically, Vitrolife AB's own OCF Yield % has ranged from 0.55 to 6.08 over the past decade. While the company's 10-year median is 2.09 vs. the industry median of 1.68, Vitrolife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.68, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current OCF Yield % of 5.98 is 256% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current OCF Yield % is 5.98, which is 186% above median its own 10-year median of 2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.23, compared to a current price of kr91.10 — trading 43.8% below its estimated fair value. The current OCF Yield % is 5.98, which is 186% above median its 10-year median of 2.09 and 256% above the Medical Devices & Instruments industry median of 1.68. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current OCF Yield % is 5.98 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr91.10 is trading 43.8% below its estimated GF Value™ of kr162.23.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
OCF Yield %: 5.98 (186% above median its 10-year median of 2.09)
GF Value™: kr162.23 vs. price of kr91.10 (43.8% below fair value)
Industry Position: 256% above the Medical Devices & Instruments median (#243 of 853)
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score
Get the complete analysis for OSTO:VITR
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
